Keymed Biosciences (FRA:64Z) Total Equity: €336.46 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:64Z Keymed Biosciences Inc FRA:64Z
44 GF Score
Price €8.45
GF Value €18.50
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Keymed Biosciences Total Equity?

Keymed Biosciences FRA:64Z +1.81% 44 Total Equity is €336.46 Mil as of Dec. 2025. GuruFocus rates FRA:64Z with a GF Score™ of 44/100 and a GF Value™ of €18.50 (Possible Value Trap). The stock has 5 warning signs investors should review.

Keymed Biosciences's total equity for the quarter that ended in Dec. 2025 was €336.46 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Keymed Biosciences Total Equity Historical Data

* Premium members only.

The historical data trend for Keymed Biosciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Keymed Biosciences Total Equity Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 506.52 452.15 383.59 324.67 336.46

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 383.59 337.70 324.67 385.82 336.46
FRA:64Z
44GF Score
Keymed Biosciences Inc FRA:64Z
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Keymed Biosciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Keymed Biosciences's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=511.383-174.919
=336.46

Keymed Biosciences's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=511.383-174.919
=336.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €336.46 Mil mean?
Keymed Biosciences (FRA:64Z) has a Total Equity of €336.46 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Keymed Biosciences and its competitors.
Is Keymed Biosciences' Total Equity too high?
Keymed Biosciences' current Total Equity is €336.46 Mil. Overall, Keymed Biosciences has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Total Equity compare to VRTX and REGN?
Keymed Biosciences' Total Equity of €336.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Keymed Biosciences and its competitors. Keymed Biosciences's current Total Equity is €336.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Keymed Biosciences (FRA:64Z) is currently considered Possible Value Trap. The stock's GF Value™ is €18.50, compared to a current price of €8.45 — trading 54.3% below its estimated fair value. The current Total Equity is €336.46 Mil. Keymed Biosciences' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Total Equity is €336.46 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?

Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued. The current stock price of €8.45 is trading 54.3% below its estimated GF Value™ of €18.50. GuruFocus considers Keymed Biosciences to be Possible Value Trap.

Key valuation signals for FRA:64Z:

  • Total Equity: €336.46 Mil
  • GF Value™: €18.50 vs. price of €8.45 (54.3% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Keymed Biosciences Business Description

Other Exchanges 02162:Hong Kong
Address No. 669 Fenghuang Road, Shuangliu District, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
44GF Score

Get the complete analysis for FRA:64Z

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.45
Price
€18.50
GF Value